These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36118716)

  • 1. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.
    Kellon EM; Gustafson KM
    Open Vet J; 2022; 12(4):511-518. PubMed ID: 36118716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
    Kellon EM; Gustafson KM
    Open Vet J; 2023 Mar; 13(3):365-375. PubMed ID: 37026076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study.
    Lindåse S; Nostell K; Forslund A; Bergsten P; Bröjer J
    J Vet Intern Med; 2023; 37(6):2520-2528. PubMed ID: 37864426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between hyperinsulinaemia and laminitis severity at the time of pituitary pars intermedia dysfunction diagnosis.
    Tadros EM; Fowlie JG; Refsal KR; Marteniuk J; Schott HC
    Equine Vet J; 2019 Jan; 51(1):52-56. PubMed ID: 29761574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
    Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
    BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.
    Meier AD; de Laat MA; Reiche DB; Pollitt CC; Walsh DM; McGree JM; Sillence MN
    Domest Anim Endocrinol; 2018 Apr; 63():1-9. PubMed ID: 29172109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamellar pathology in horses with pituitary pars intermedia dysfunction.
    Karikoski NP; Patterson-Kane JC; Singer ER; McFarlane D; McGowan CM
    Equine Vet J; 2016 Jul; 48(4):472-8. PubMed ID: 25869529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction.
    Horn R; Bamford NJ; Afonso T; Sutherland M; Buckerfield J; Tan RHH; Secombe CJ; Stewart AJ; Bertin FR
    Equine Vet J; 2019 Jul; 51(4):440-445. PubMed ID: 30417404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ; Menzies-Gow NJ; Mair TS
    Equine Vet J; 2014 Mar; 46(2):249-51. PubMed ID: 23663105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion/referral equine hospital.
    Karikoski NP; Horn I; McGowan TW; McGowan CM
    Domest Anim Endocrinol; 2011 Oct; 41(3):111-7. PubMed ID: 21696910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.
    Meier A; Reiche D; de Laat M; Pollitt C; Walsh D; Sillence M
    PLoS One; 2018; 13(9):e0203655. PubMed ID: 30212530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological investigation of insulin dysregulation in Shetland and Welsh ponies in Australia.
    Clark BL; Norton EM; Bamford NJ; Randhawa IAS; Kemp KL; McCue ME; Bertin FR; Stewart AJ
    Equine Vet J; 2024 Mar; 56(2):281-290. PubMed ID: 38173146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA; Sloan L
    Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic, hormonal, and clinical characteristics of equine endocrinopathic laminitis.
    de Laat MA; Sillence MN; Reiche DB
    J Vet Intern Med; 2019 May; 33(3):1456-1463. PubMed ID: 30697823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demographic, morphologic, hormonal and metabolic factors associated with the rate of improvement from equine hyperinsulinaemia-associated laminitis.
    Sillence M; Meier A; de Laat M; Klee R; Reiche D
    BMC Vet Res; 2022 Jan; 18(1):49. PubMed ID: 35042535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.